162 related articles for article (PubMed ID: 11682253)
1. Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers.
Zwanzger P; Baghai TC; Schuele C; Ströhle A; Padberg F; Kathmann N; Schwarz M; Möller HJ; Rupprecht R
Neuropsychopharmacology; 2001 Nov; 25(5):699-703. PubMed ID: 11682253
[TBL] [Abstract][Full Text] [Related]
2. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study.
Zwanzger P; Eser D; Aicher S; Schüle C; Baghai TC; Padberg F; Ella R; Möller HJ; Rupprecht R
Neuropsychopharmacology; 2003 May; 28(5):979-84. PubMed ID: 12700707
[TBL] [Abstract][Full Text] [Related]
3. Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers.
Zwanzger P; Eser D; Padberg F; Baghai TC; Schule C; Rötzer F; Ella R; Möller HJ; Rupprecht R
Depress Anxiety; 2003; 18(3):140-3. PubMed ID: 14625878
[TBL] [Abstract][Full Text] [Related]
4. Megestrol attenuates the hormonal response to CCK-4-induced panic attacks.
Raedler TJ; Jahn H; Goedeken B; Gescher DM; Kellner M; Wiedemann K
Depress Anxiety; 2006; 23(3):139-44. PubMed ID: 16470820
[TBL] [Abstract][Full Text] [Related]
5. Panic induction with cholecystokinin-tetrapeptide (CCK-4) Increases plasma concentrations of the neuroactive steroid 3alpha, 5alpha tetrahydrodeoxycorticosterone (3alpha, 5alpha-THDOC) in healthy volunteers.
Eser D; di Michele F; Zwanzger P; Pasini A; Baghai TC; Schüle C; Rupprecht R; Romeo E
Neuropsychopharmacology; 2005 Jan; 30(1):192-5. PubMed ID: 15467707
[TBL] [Abstract][Full Text] [Related]
6. Effects of repetitive transcranial magnetic stimulation (rTMS) on panic attacks induced by cholecystokinin-tetrapeptide (CCK-4).
Zwanzger P; Eser D; Völkel N; Baghai TC; Möller HJ; Rupprecht R; Padberg F
Int J Neuropsychopharmacol; 2007 Apr; 10(2):285-9. PubMed ID: 16817979
[TBL] [Abstract][Full Text] [Related]
7. Differential effects to CCK-4-induced panic by dexamethasone and hydrocortisone.
Demiralay C; Jahn H; Kellner M; Yassouridis A; Wiedemann K
World J Biol Psychiatry; 2012 Oct; 13(7):526-34. PubMed ID: 22111662
[TBL] [Abstract][Full Text] [Related]
8. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers.
Bradwejn J; Koszycki D; Paradis M; Reece P; Hinton J; Sedman A
Biol Psychiatry; 1995 Dec; 38(11):742-6. PubMed ID: 8580227
[TBL] [Abstract][Full Text] [Related]
9. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder.
Ströhle A; Holsboer F; Rupprecht R
Neuropsychopharmacology; 2000 Mar; 22(3):251-6. PubMed ID: 10693152
[TBL] [Abstract][Full Text] [Related]
10. One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI.
Schunck T; Mathis A; Erb G; Namer IJ; Hode Y; Demazières A; Luthringer R
J Psychopharmacol; 2011 Jan; 25(1):52-9. PubMed ID: 20498136
[TBL] [Abstract][Full Text] [Related]
11. The acute antipanic and anxiolytic activity of aerobic exercise in patients with panic disorder and healthy control subjects.
Ströhle A; Graetz B; Scheel M; Wittmann A; Feller C; Heinz A; Dimeo F
J Psychiatr Res; 2009 Aug; 43(12):1013-7. PubMed ID: 19289240
[TBL] [Abstract][Full Text] [Related]
12. Copeptin - A potential endocrine surrogate marker of CCK-4-induced panic symptoms?
Demiralay C; Agorastos A; Yassouridis A; Jahn H; Wiedemann K; Kellner M
Psychoneuroendocrinology; 2017 Feb; 76():14-18. PubMed ID: 27871026
[TBL] [Abstract][Full Text] [Related]
13. Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers.
Koszycki D; Zacharko RM; Le Mellédo JM; Bradwejn J
Depress Anxiety; 1998; 8(1):1-7. PubMed ID: 9750972
[TBL] [Abstract][Full Text] [Related]
14. Neuropeptide S receptor gene variation modulates anterior cingulate cortex Glx levels during CCK-4 induced panic.
Ruland T; Domschke K; Schütte V; Zavorotnyy M; Kugel H; Notzon S; Vennewald N; Ohrmann P; Arolt V; Pfleiderer B; Zwanzger P
Eur Neuropsychopharmacol; 2015 Oct; 25(10):1677-82. PubMed ID: 26235955
[TBL] [Abstract][Full Text] [Related]
15. Impact of loudness dependency of auditory evoked potentials on the panic response to CCK-4.
Eser D; Leicht G; Baghai T; Pogarell O; Schüle C; Karch S; Nothdurfter C; Rupprecht R; Mulert C
J Psychiatr Res; 2009 Jan; 43(4):393-400. PubMed ID: 18534623
[TBL] [Abstract][Full Text] [Related]
16. Plasma gamma-amino-butyric acid (GABA) levels in cholecystokinine-tetrapeptide (CCK-4) induced anxiety.
Zwanzger P; Jarry H; Eser D; Padberg F; Baghai T; Schule C; Ella R; Möller HJ; Rupprecht R
J Neural Transm (Vienna); 2003 Mar; 110(3):313-6. PubMed ID: 12658378
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study.
Eser D; Schüle C; Baghai T; Floesser A; Krebs-Brown A; Enunwa M; de la Motte S; Engel R; Kucher K; Rupprecht R
Psychopharmacology (Berl); 2007 Jul; 192(4):479-87. PubMed ID: 17318504
[TBL] [Abstract][Full Text] [Related]
18. Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males.
Goettel M; Fuertig R; Mack SR; Just S; Sharma V; Wunder A; den Boer J
CNS Drugs; 2023 Dec; 37(12):1099-1109. PubMed ID: 38019356
[TBL] [Abstract][Full Text] [Related]
19. Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition.
Otte C; Moritz S; Yassouridis A; Koop M; Madrischewski AM; Wiedemann K; Kellner M
Neuropsychopharmacology; 2007 Jan; 32(1):232-8. PubMed ID: 17035932
[TBL] [Abstract][Full Text] [Related]
20. Acute shift in glutamate concentrations following experimentally induced panic with cholecystokinin tetrapeptide--a 3T-MRS study in healthy subjects.
Zwanzger P; Zavorotnyy M; Gencheva E; Diemer J; Kugel H; Heindel W; Ruland T; Ohrmann P; Arolt V; Domschke K; Pfleiderer B
Neuropsychopharmacology; 2013 Aug; 38(9):1648-54. PubMed ID: 23463151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
